Clinical implications of neuropsychiatric systemic lupus erythematosus

Advances in Psychiatric Treatment

Volumn 15, Issue 6, 2009, Pages 451-458

  Mak, Anselm ^a   Ho, Roger Chun Man ^b   Lau, Chak Sing ^c  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; AUTOANTIBODY; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; FLUOXETINE; METHYLPREDNISOLONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE;

ABSENCE OF SIDE EFFECTS; AGRANULOCYTOSIS; ANXIETY DISORDER; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE THERAPY; DEPRESSION; ERYTHEMA; FIBROMYALGIA; HUMAN; IMMUNOPATHOGENESIS; KINESIOTHERAPY; LUPUS LIKE SYNDROME; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; REVIEW; SEIZURE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 77949481097     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.108.005785     Document Type: Review

References (53)

1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism; 42: 599-608.
2. Appenzeller S, Cendes F, Castallat L (2008) Acute psychosis in systemic lupus erythematosus. Rheumatology International; 28: 237-43.
3. Arnett FC, Reveille JD, Moutsopoulos HM, et al (1996) Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis and Rheumatism; 39: 1833-9.
4. Baca V, Lavalle C, García R, et al (1999) Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. Journal of Rheumatology; 26: 432-9.
5. Bodani M, Kopelman MD (2003) A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus. Lupus; 12: 947-9.
6. Brey RL, Holliday SL, Saklad AR, et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology ; 58: 1214-20.
7. Cassis TB, Callen JP (2005) Bupropion-induced subacute cutaneous lupus erythematosus. Australasian Journal of Dermatology; 46: 266-9.
8. Ditmore BG, Malek-Ahmadi P, Millis DM, et al (1992) Manic psychosis and catatonia stemming from systemic lupus erythematosus: response to ECT. Convulsive Therapy; 8: 33-7.
9. Douglas CJ, Schwartz HI (1982) ECT for depression caused by lupus cerebritis: a case report. American Journal of Psychiatry; 139: 1631-2.
10. Driver CB, Wallace DJ, Lee JC, et al (2008) Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism (Arthritis Care & Research); 59: 332-7.
11. Emmer BJ, Steup-Beekman GM, Steens SC, et al (2008) Correlation of magnetization transfer ratio histogram parameters with neuropsychiatric systemic lupus erythematosus criteria and proton magnetic resonance spectroscopy: association of magnetization transfer ratio peak height with neuronal and cognitive dysfunction. Arthritis and Rheumatism; 58: 1451-7.
12. Fallon BA, Liebowitz MR (1991) Fluoxetine and extrapyramidal symptoms in CNS lupus. Journal of Clinical Psychopharmacology; 11: 147-8.
13. Fernandez G, Gorriti M, Garcia-Vicuna R, et al (2007) Psychosis leading to the diagnosis of unrecognized systemic lupus erythematosus: a case report. Rheumatology International; 27: 883-5.
14. Garety PA, Kuipers L, Fowler D, et al (1994) Cognitive behavioural therapy for drug resistant psychosis. British Journal of Medical Psychology; 67: 259-71.
15. George-Chandy A, Trysberg E, Eriksson K (2008) Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Research and Therapy; 10: R97.
16. Goldberg D, Huxley P (1992) Common Mental Disorders. Routledge.
17. Harth Y, Rapoport M (1996) Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Safety; 14: 252-9.
18. Hanly JG, Harrison MJ (2005) Management of neuropsychiatric lupus. Best Practice and Research Clinical Rheumatology; 19: 799-821.
19. Herrmann N, Lanctôt KL (2005) Do atypical antipsychotics cause stroke? Central Nervous System Drugs; 19: 91-103.
20. Hill VA, Hepburn NC (1998) Sertraline associated discoid lupus erythematosus-like eruption. Journal of the Royal Army Medical Corps; 144: 109-10.
21. Hughes M, Sundgren PC, Fan X, et al (2007) Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigen values in different regions of the brain. Acta Radiologica; 48: 213-22.
22. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology; 20: 201-25.
23. Kozora E, Arciniegas D, Zhang L, et al (2007) Neuropsychological patterns in systemic lupus erythematosus patients with depression. Arthritis Research and Therapy; 9: R48.
24. Krupp LB, LaRocca NG, Muir J, et al (1990) A study of fatigue in systemic lupus erythematosus. Journal of Rheumatology; 17: 1450-2.
25. Kuipers E, Garety P, Fowler D, et al (1997) London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of treatment phase. British Journal of Psychiatry; 171: 319-27.
26. Lapteva L, Nowak M, Yarboro CH, et al (2006) Anti-N-methyl- D-aspartate receptor antibodies, cognitive dysfunction, and depression in systematic lupus erythematosus. Arthritis and Rheumatism; 54: 2505-14.
27. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. New England Journal of Medicine; 330: 613-22.
28. Mak A, Mok CC, Chu WP, et al (2007a) Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus; 16: 28-34.
29. Mak A, Chan BP, Yeh IB, et al (2007b) Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology; 47: 256-62.
30. Maes M, Meltzer HY, Bosmans E, et al (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorder; 34: 301-9.
31. McKinley P, Ouellette SC, Winkel G (1995) The contributions of disease activity, sleep patterns and depression to fatigue in systemic lupus erythematosus. Arthritis and Rheumatism; 38: 826-34.
32. Monastero R, Bettini P, Del Zotto E, et al (2001) Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. Journal of Neurological Sciences; 184: 33-9.
33. Nishimura K, Omori M, Horikawa N, et al (2003) Risperidone in the treatment of acute confusional state due to neuropsychiatric lupus erythematosus: case report. International Journal of Psychiatry in Medicine; 33: 299-303.
34. Petri M (2007) The Hopkins Lupus Pregnancy Center: ten key issues in manage ment. Rheumatic Diseases Clinics of North America; 33: 227-35.
35. Pollmächer T, Haack M, Schuld A, et al (2002) Low levels of circulating inflammatory cytokines. Do they affect human brain functions? Brain, Behaviour, and Immunity; 16: 525-32.
36. Poole JL, Atanasoff G, Pelsor JC, et al (2006) Comparison of a self-report and performance-based test of disability in people with systemic lupus erythematosus. Disability and Rehabilitation; 28: 653-8.
37. Stojanovich L, Zandman-Goddard G, Pavlovich S, et al (2007) Psychiatric manifestations of systemic lupus erythematosus. Autoimmunity Review; 6: 421-6.
38. Stoll T, Kauer Y, Buchi S, et al (2001) Prediction of depression in systemic lupus erythematosus patients using SF-36 Mental Health scores. Rheumatology; 40: 695-8.
39. Su JA, Wu CH, Tsang HY (2007) Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report. General Hospital Psychiatry; 29: 75-7.
40. Sun XY, Shi J, Han L, et al (2008) Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus. Journal of Clinical Laboratory Analysis; 22: 271-7.
41. Tan HY, Chen Q, Sust S, et al (2007) Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proceedings of the National Academy of Sciences of the United States of America; 104: 12536-41.
42. Taylor J, Skan J, Erb N, et al (2000) Lupus patients with fatigue: is there a link with fibromyalgia syndrome? Rheumatology; 39: 620-3.
43. Tench CM, McCurdie I, White PD, et al (2000) The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology; 39: 1249-54.
44. Tench CM, McCarthy J, McCurdie I, et al (2003) Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology; 42: 1050-4.
45. Tektonidou MG, Varsou N, Kotoulas G, et al (2006) Cognitive deficits in patients with antiphospholipid syndrome. Archives of Internal Medicine; 166: 2278-84.
46. Ward MM, Marx AS, Barry NN (2002) Psychological distress and changes in the activity of systemic lupus erythematosus. Rheumatology; 41: 184-8.
47. Wekking EM (1993) Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosomatic Medicine; 55: 219-28.
48. Welsh RC, Rahbar H, Foerster B, et al (2007) Brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus with new acute neurological symptoms. Journal of Magnetic Resonance Imaging; 26: 541-51.
49. Wolkowitz OM, Reus VI, Canick J, et al (1997) Glucocorticoid medication, memory and steroid psychosis in medical illness. Annals of the New York Academy of Sciences; 823: 81-96.
50. Wykes T, Reeder C, Corner J, et al (1999) The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophrenia Bulletin; 25: 291-307.
51. Yang XY, Lin J, Lu XY, et al (2008) Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuro psychiatric systemic lupus erythematosus. Clinical Rheumatology; 27: 353-7.
52. Yoshida A, Shishido F, Kato K, et al (2007) Evaluation of cerebral perfusion in patients with neuropsychiatric systemic lupus erythematosus using 123I-IMP SPECT. Annals of Nuclear Medicine; 21: 151-8.
53. Zhang L, Harrison M, Heier LA, et al (2007) Diffusion changes in patients with systemic lupus erythematosus. Magnetic Resonance Imaging; 25: 399-405.